{"id":34436,"date":"2025-05-05T09:30:15","date_gmt":"2025-05-05T13:30:15","guid":{"rendered":"https:\/\/advisory.avalerehealth.com\/?p=34436"},"modified":"2025-05-02T13:43:09","modified_gmt":"2025-05-02T17:43:09","slug":"understanding-the-scope-of-cidraps-vaccine-integrity-project","status":"publish","type":"post","link":"https:\/\/advisory.avalerehealth.com\/insights\/understanding-the-scope-of-cidraps-vaccine-integrity-project","title":{"rendered":"Understanding the Scope of CIDRAP\u2019s Vaccine Integrity Project"},"content":{"rendered":"

In late April, the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota announced the creation of the Vaccine Integrity Project<\/a> (VIP) \u201cdedicated to safeguarding vaccine use in the US.\u201d The first step for its eight-person steering committee<\/a> is to conduct listening sessions with immunization professionals to understand how non-governmental bodies may engage in the vaccine policy landscape.<\/p>\n

Given the current structure of US immunization guidelines and policy development, it remains to be seen how the VIP will be integrated as it evolves. Below, we explore four outstanding questions that will help interpret the role and impact of the VIP within the vaccine ecosystem.<\/p>\n

\"\"<\/p>\n

1.\u00a0 How can the VIP inform US immunization policy, and how can it not?<\/strong><\/p>\n

In a press release<\/a> announcing the launch of the VIP, CIDRAP Director Dr. Michael Osterholm alluded to environmental changes that may impact current science-based vaccine recommendation processes and safety and effectiveness data appraisals. This announcement follows a two-month delay<\/a> of a scheduled Advisory Committee on Immunization Practices (ACIP) meeting and the cancellation<\/a> of a Food and Drug Administration (FDA) advisory committee meeting to formulate strain composition for the 2025-2026 seasonal influenza vaccine. These deviations from longstanding vaccine evidence review and recommendation processes have raised concerns among immunization stakeholders, many of whom rely on ACIP recommendations to guide their vaccination policies and practices.<\/p>\n

The ACIP formulates recommendations for vaccine use based on a robust review of clinical, safety, and cost-effectiveness data. These recommendations then require endorsement by the Director of the Centers for Disease Control and Prevention (CDC) and subsequently inform federal coverage policy. Most clinical societies adopt ACIP recommendations or leverage the clinical considerations for healthcare professionals and public health officials to develop protocols for specific patient populations.<\/p>\n

2. How can VIP guidance augment existing immunization guidelines?<\/strong><\/p>\n

Several medical professional societies develop immunization guidelines. Specifically, the childhood and adolescent immunization schedules, which are reviewed and voted on annually by the ACIP, are subsequently approved by the American Academy of Pediatrics, the American Academy of Family Physicians (AAFP), and the American College of Obstetricians and Gynecologists (ACOG). The adult schedule is approved by AAFP, ACOG, the American College of Physicians, and the American College of Nurse Midwives.<\/p>\n

Current society immunization guidelines mirror the ACIP\u2019s recommendations and clinical considerations (e.g., vaccine use in special populations, like immunocompromised individuals). Absent these recommendations and additional guidance from the ACIP, societies may conduct their own guideline development processes for vaccination and look to the VIP to inform them. Conversely, the VIP may seek participation from these medical societies to inform its own vaccine evaluation and clinical guidance formulation.<\/p>\n

3. How will the VIP review clinical and economic evidence for new products to inform guidance?<\/strong><\/p>\n

The ACIP maintains a systematic evidence review process to inform its vaccine use recommendations. Separately, guideline-developing medical societies also maintain their own evidence review processes, which may or may not align with federal advisory frameworks. While it is unclear how the VIP will review evidence going forward, it may draw from current examples to inform its own framework. A process that aligns more closely with current federal standards (e.g., the ACIP\u2019s Evidence to Recommendations framework) may allow for more seamless integration into the existing policy environment, while aligning with any number of medical societies may support a centralized, accessible repository of guidance across provider types.<\/p>\n

4. How will payers use VIP guidance in immunization coverage decisions?<\/strong><\/p>\n

Federal law anchors vaccine coverage without cost sharing to ACIP recommendations for most insurance coverage markets, with some exceptions:<\/p>\n